Format

Send to

Choose Destination
Ophthalmol Ther. 2017 Dec;6(2):233-241. doi: 10.1007/s40123-017-0098-2. Epub 2017 Jul 20.

An Update on Implants for Minimally Invasive Glaucoma Surgery (MIGS).

Author information

1
Maidstone & Tunbridge Wells NHS Trust, Maidstone, UK. e.ansari@nhs.net.
2
University of Kent, Canterbury, UK. e.ansari@nhs.net.

Abstract

For several years, the gold standard for surgical treatment of glaucoma has been trabeculectomy. Although very successful at reducing intraocular pressure (IOP), there are several potential complications of trabeculectomy, including sight-threatening ones. This has stimulated much research aimed at the development of new and effective procedures to lower IOP with an enhanced safety profile. Minimally invasive glaucoma surgery (MIGS) procedures prioritise patient safety but also demonstrate efficacy in reducing IOP. We performed an online search of peer-reviewed literature using PubMed, entering keywords relevant to this clinical discipline. In summary, there is a lack of long-term safety and efficacy data, a lack of comparative data and a lack of data on standalone (i.e. without simultaneous cataract surgery) procedures. Most implants are not yet FDA approved. Although not exhaustive, since it does not discuss MIGS procedures that are not implants, this article summarises the range of different MIGS implants that are available to the ophthalmic surgeon.

KEYWORDS:

CyPass; Glaucoma; Hydrus; Implant; MIGS; Microshunt; Phaco; Stent; XEN; iStent

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center